Ackermann Michael's Form 4 filing
Tarsus Pharmaceuticals, Inc.TARS · filed Aug 10, 2021
- Accession no.
- 0001209191-21-050631
- Filed
- Aug 10, 2021
- Trade date
- Aug 6-9, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $95.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ackermann MichaelCIK 0001791249 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2021 | Common Stock | SSaleDisposed | −3,129 | $25.00 | −$78,225 | 1,228,669 | Direct | |
| Aug 9, 2021 | Common Stock | SSaleDisposed | −700 | $25.00 | −$17,500 | 1,227,969 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.